Cited by 310Alzheimer's disease research and treatmentsFatty Acid Research and HealthDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study

Open access
Snowden, Stuart G., Ebshiana, Amera A., Hye, Abdul, An, Yang, Pletnikova, Olga, O’Brien, Richard, Troncoso, John, Legido-Quigley, Cristina, Thambisetty, Madhav·2017·PLOS Medicine

Abstract

BACKGROUND: The metabolic basis of Alzheimer disease (AD) pathology and expression of AD symptoms is poorly understood. Omega-3 and -6 fatty acids have previously been linked to both protective and pathogenic effects in AD. However, to date little is known about how the abundance of these species is affected by differing levels of disease pathology in the brain. METHODS AND FINDINGS: We performed metabolic profiling on brain tissue samples from 43 individuals ranging in age from 57 to 95 y old who were stratified into three groups: AD (N = 14), controls (N = 14) and "asymptomatic Alzheimer's disease" (ASYMAD), i.e., individuals with significant AD neuropathology at death but without evidence for cognitive impairment during life (N = 15) from the autopsy sample of the Baltimore Longitudinal Study of Aging (BLSA). We measured 4,897 metabolite features in regions both vulnerable in the middle frontal and inferior temporal gyri (MFG and ITG) and resistant (cerebellum) to classical AD pathology. The levels of six unsaturated fatty acids (UFAs) in whole brain were compared in controls versus AD, and the differences were as follows: linoleic acid (p = 8.8 x 10-8, FC = 0.52, q = 1.03 x 10-6), linolenic acid (p = 2.5 x 10-4, FC = 0.84, q = 4.03 x 10-4), docosahexaenoic acid (p = 1.7 x 10-7, FC = 1.45, q = 1.24 x 10-6), eicosapentaenoic acid (p = 4.4 x 10-4, FC = 0.16, q = 6.48 x 10-4), oleic acid (p = 3.3 x 10-7, FC = 0.34, q = 1.46 x 10-6), and arachidonic acid (p = 2.98 x 10-5, FC = 0.75, q = 7.95 x 10-5). These fatty acids were strongly associated with AD when comparing the groups in the MFG and ITG, respectively: linoleic acid (p < 0.0001, p = 0.0006), linolenic acid (p < 0.0001, p = 0.002), docosahexaenoic acid (p < 0.0001, p = 0.0024), eicosapentaenoic acid (p = 0.0002, p = 0.0008), oleic acid (p < 0.0001, p = 0.0003), and arachidonic acid (p = 0.0001, p = 0.001). Significant associations were also observed between the abundance of these UFAs with neuritic plaque and neurofibrillary tangle burden as well as domain-specific cognitive performance assessed during life. Based on the regional pattern of differences in brain tissue levels of these metabolites, we propose that alterations in UFA metabolism represent both global metabolic perturbations in AD as well as those related to specific features of AD pathology. Within the middle frontal gyrus, decrements in linoleic acid, linolenic acid, and arachidonic acid (control>ASYMAD>AD) and increases in docosahexanoic acid (AD>ASYMAD>control) may represent regionally specific threshold levels of these metabolites beyond which the accumulation of AD pathology triggers the expression of clinical symptoms. The main limitation of this study is the relatively small sample size. There are few cohorts with extensive longitudinal cognitive assessments during life and detailed neuropathological assessments at death, such as the BLSA. CONCLUSIONS: The findings of this study suggest that unsaturated fatty acid metabolism is significantly dysregulated in the brains of patients with varying degrees of Alzheimer pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002266

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Boxplots showing the effect of disease status on the abundance of six UFAs in the CB, ITG, and MFG. Dysregulation of six UFAs shown by boxplots of three disease statuses separated by brain region A) arachidonic acid (AA), B) oleic acid (OLA), C) eicosapentaenoic acid (EPA), D) linolenic acid (LNA), E) linoleic acid (LA), F) docosahexaenoic acid (DHA). AS, asymptomatic Alzheimer; CN, control; DM, Dementia/Alzheimer.
Fig 1 Boxplots showing the effect of disease status on the abundance of six UFAs in the CB, ITG, and MFG. Dysregulation of six UFAs shown by boxplots of three disease statuses separated by brain region A) arachidonic acid (AA), B) oleic acid (OLA), C) eicosapentaenoic acid (EPA), D) linolenic acid (LNA), E) linoleic acid (LA), F) docosahexaenoic acid (DHA). AS, asymptomatic Alzheimer; CN, control; DM, Dementia/Alzheimer.CC0 · PubMed Central
Fig 2 Forest plot showing the relationship of the abundance of six UFAs in the MFG and five measures of cognitive performance. A) Association between UFA levels and longitudinal cognitive performance. B) Association between UFA levels and cognitive performance at the last visit prior to death. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; LNA, linolenic acid; OLA, oleic acid; STD, Standard.
Fig 2 Forest plot showing the relationship of the abundance of six UFAs in the MFG and five measures of cognitive performance. A) Association between UFA levels and longitudinal cognitive performance. B) Association between UFA levels and cognitive performance at the last visit prior to death. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; LNA, linolenic acid; OLA, oleic acid; STD, Standard.CC0 · PubMed Central
Fig 3 Overview of omega-3 and omega-6 UFA metabolism showing the potential association between the measured UFAs. Metabolites highlighted in red have been associated with increased risk of disease pathology, with metabolites highlighted in green have been associated with decreased risk of disease pathology. COX, cyclooxygenase; CYP450, cytochrome P450; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LCD, lineoyl-CoA desaturase; LOX, lipoxygenase; PLA2, phospholipase A2.
Fig 3 Overview of omega-3 and omega-6 UFA metabolism showing the potential association between the measured UFAs. Metabolites highlighted in red have been associated with increased risk of disease pathology, with metabolites highlighted in green have been associated with decreased risk of disease pathology. COX, cyclooxygenase; CYP450, cytochrome P450; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LCD, lineoyl-CoA desaturase; LOX, lipoxygenase; PLA2, phospholipase A2.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

Sorted by citations

Items 101–200 of 310

Metadata

Authors
Snowden, S. G., Ebshiana, A. A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Legido-Quigley, C., & Thambisetty, M.
Affiliations
  • King's College London (GB)
  • National Institute on Aging (US)
  • Duke University (US)
  • Johns Hopkins University (US)
Corresponding author
Thambisetty, Madhav
Venue
PLOS Medicine
Published
2017-03-21
Volume
14
Issue
3
Pages
e1002266
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2600991905
Cited by
309
References
68
Citations by year
2026: 21 · 2025: 39 · 2024: 33 · 2023: 32 · 2022: 30 · 2021: 42 · 2020: 42 · 2019: 35 · 2018: 22 · 2017: 12
FWCI
22.47
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, public-domain)
Funders
  • Innovative Medicines Initiative. (European Medical Information Framework grant agreement no. 115372)
  • Innovative Medicines Initiative (European Medical Information Framework grant agreement no. 115372)
  • libyan cultural attache (7922)
  • Intramural Research Program of the NIH, National Institute on Aging
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, brain fatty acid metabolism, unsaturated fatty acids, omega-3 fatty acids, omega-6 fatty acids, docosahexaenoic acid, eicosapentaenoic acid, linoleic acid, arachidonic acid, linolenic acid, oleic acid, Alzheimer's disease pathology, cognitive performance, middle frontal gyrus, inferior temporal gyrus, cerebellum
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Fatty Acids, Female, Humans, Longitudinal Studies, Male, Middle Aged, Baltimore, Metabolome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review